Aromatase inhibitors (AI) have been replacing tamoxifen (TAM) as adjuvant hormonal therapy for postmenopausal women diagnosed with early stage, hormone receptor (HR)-positive breast cancer. This evidence concerns the gene CYP19A1 and breast carcinoma.